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BUC

:   bladder urothelial carcinoma

CHX

:   cycloheximide

Co‐IP

:   co‐immunoprecipitation

DAPI

:   2‐(4‐amidinophenyl)‐1H‐indole‐6‐carboxamidine

EGFR

:   epidermal growth factor receptor

HMG

:   high mobility group

IHC

:   immunohistochemistry

miRNA

:   microRNA

OS

:   overall survival

PBST

:   PBS‐Tween 20

qRT‐PCR

:   quantitative RT‐PCR

RC

:   radical cystectomy

SLC12A5

:   solute carrier family 12 member 5

SOX18

:   SRY‐box transcription factor 18

1. INTRODUCTION {#cas14502-sec-0001}
===============

BUC ranks ninth among the most commonly diagnosed malignancies and is the 13th highest cause of cancer‐related death across the world.[^1^](#cas14502-bib-0001){ref-type="ref"} In the clinical management of BUC,[^2^](#cas14502-bib-0002){ref-type="ref"}, [^3^](#cas14502-bib-0003){ref-type="ref"} its etiology, and biomarkers for diagnosis, prognosis, or prediction are well known.[^4^](#cas14502-bib-0004){ref-type="ref"}, [^5^](#cas14502-bib-0005){ref-type="ref"} Superficial and invasive BUC have available treatment options, however there are limited therapeutic options for metastatic disease, thus it remains a serious clinical challenge. To date, patients with BUC with tumor metastasis have had no available and effective therapies. Therefore, to develop more efficient anticancer treatments, the molecular mechanisms underlying the progression and metastasis in BUC should be determined.

*SLC12A5* gene, also known as *KCC2*, is located on chromosome 20q13, which among human cancers is one of the most frequently amplified regions.[^6^](#cas14502-bib-0006){ref-type="ref"} SLC12A5 (originally known as an integral membrane KCl cotransporter) was reported to maintain chloride homeostasis in neurons. However, recent studies have shown that mutation and abnormal expression of SLC12A5 is involved in the tumorigenesis and progression of some human cancers.[^7^](#cas14502-bib-0007){ref-type="ref"}, [^8^](#cas14502-bib-0008){ref-type="ref"}, [^9^](#cas14502-bib-0009){ref-type="ref"}, [^10^](#cas14502-bib-0010){ref-type="ref"}, [^11^](#cas14502-bib-0011){ref-type="ref"}, [^12^](#cas14502-bib-0012){ref-type="ref"} Recently, we found that high expression of SLC12A5 is an independent molecular marker for shortened survival of patients with BUC. Furthermore, downregulation of the *SLC12A5* gene, combined with cDNA gene chip analysis, confirmed that matrix metalloproteinase 7 (*MMP7*) is the major downstream target gene of SLC12A5 during induction of BUC invasiveness and metastasis.[^13^](#cas14502-bib-0013){ref-type="ref"} SLC12A5's tumor‐specific regulation and its downstream targets should be determined, as this would reveal their potentially important clinical applications. Consequently, the aim of the present study was to investigate the oncogenic role of SLC12A5 and its molecular mechanisms in BUC.

In this study, we evaluated expression status of SLC12A5 in a series of primary BUCs from RC specimens and its clinical significance. We also demonstrated that SOX18 is a novel binding partner for SLC12A5. SOX18 interacts with SLC12A5 in vitro and in vivo. Moreover, we provide evidence that SLC12A5 interacts with SOX18, and then upregulates downstream *MMP7* expression to promote BUC cell progression and metastasis. Our findings suggest that SLC12A5 is an oncogene and may be a prognostic factor in BUC that exerts its function by upregulating MMP7 via SOX18.

2. MATERIALS AND METHODS {#cas14502-sec-0002}
========================

2.1. Cell lines and clinical samples {#cas14502-sec-0003}
------------------------------------

The American Type Culture Collection (ATCC) provided 7 human BUC cell lines (UM‐UC3, T24, J82, 5637, RT4, EJ, BIU87), and SV‐HUV‐1, a normal bladder uroepithelial cell line. These cell lines were grown in DMEM (Invitrogen) containing 10% fetal bovine serum. For IHC analysis, as a learning cohort, 112 patients with BUC treated with RC were selected from the Third Xiangya Hospital of Central South University and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University. The validation cohort comprised 126 patients with BUC who had been treated with RC at other institutes, including the Cancer Center and the First Affiliated Hospital, Sun Yat‐Sen University. The patients were selected based on previously described criteria.[^14^](#cas14502-bib-0014){ref-type="ref"}, [^15^](#cas14502-bib-0015){ref-type="ref"} Table [1](#cas14502-tbl-0001){ref-type="table"} describes the clinicopathological characteristics of these patients. In addition, between 2015 and 2017, the Third Xiangya Hospital of Central South University provided a panel of 20 fresh BUC tissues and matched adjacent nontumor bladder tissues, which were stored in liquid nitrogen until needed. The Ethical Committee of the Third Xiangya Hospital of Central South University (Changsha, China) approved this study.

###### 

Clinicopathological correlation of SLC12A5 expression in BUC

  Variable                                        Learning cohort   Validation cohort                                                      
  ----------------------------------------------- ----------------- ------------------- ----------- -------- ----- ----------- ----------- --------
  Age (y)                                                                                                                                  
  ≤66[^b^](#cas14502-note-0004){ref-type="fn"}    56                25 (44.6)           31 (55.4)   .57      72    34 (47.2)   38 (52.8)   .918
  ＞66                                            56                28 (50.0)           28 (50.0)            54    26 (48.1)   28 (51.9)   
  Gender                                                                                                                                   
  Male                                            90                44 (49.4)           45 (50.6)   .473     114   50 (43.9)   64 (56.1)   .009
  Female                                          22                9 (40.9)            13 (59.1)            12    10 (83.3)   2 (16.7)    
  Smoking history                                                                                                                          
  No                                              47                27 (57.4)           20 (42.6)   .068     52    26 (50.0)   26 (50.0)   .654
  Yes                                             65                26 (40.0)           39 (60.0)            74    34 (45.9)   40 (54.1)   
  Tumor size (cm)                                                                                                                          
  ≤3.6[^c^](#cas14502-note-0005){ref-type="fn"}   58                31 (53.4)           27 (46.6)   .178     71    29 (40.8)   42 (59.2)   .084
  ＞3.6                                           54                22 (40.7)           32 (59.3)            55    31 (56.4)   24 (43.6)   
  Tumor multiplicity                                                                                                                       
  Unifocal                                        35                13 (37.1)           22 (62.9)   .146     49    18 (36.7)   31 (63.3)   .051
  Multifocal                                      77                40 (51.9)           37 (48.1)            77    42 (54.5)   35 (45.5)   
  Tumor grade                                                                                                                              
  G1                                              17                13 (76.5)           4 (23.5)    .016     24    20 (83.3)   4 (16.7)    \<.001
  G2                                              43                21 (48.8)           22 (51.2)            46    19 (41.3)   27 (58.7)   
  G3                                              52                39 (36.5)           34 (63.5)            56    21 (37.5)   35 (62.5)   
  pT status                                                                                                                                
  pTa/pT1                                         31                26 (83.9)           5 (16.1)    \<.001   25    17 (68.0)   8 (32.0)    .009
  pT2                                             34                19 (55.9)           15 (44.1)            55    29 (52.7)   26 (47.3)   
  pT3                                             40                6 (15.0)            34 (85.0)            30    11 (36.7)   19 (63.3)   
  pT4                                             7                 2 (28.6)            5 (71.4)             16    3 (18.8)    13 (52.4)   
  pN status                                                                                                                                
  pN−                                             86                47 (54.7)           39 (45.3)   .005     105   57 (54.3)   48 (45.7)   .001
  pN+                                             26                6 (23.1)            20 (76.9)            21    3 (14.3)    18 (85.7)   
  Adjuvant chemotherapy                                                                                                                    
  No                                              71                47 (66.2)           24 (33.8)   \<.001   93    54 (57.0)   39 (43.0)   \<.001
  Yes                                             41                6 (14.6)            35 (85.4)            33    6 (15.2)    27 (84.8)   

Abbreviation: BUC, bladder urothelial carcinoma.

Chi‐square test.

Median age.

Median size.
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2.2. Stable cell line construction {#cas14502-sec-0004}
----------------------------------

Vectors pMSCV/SLC12A5 and pMSC/SOX18, which overexpress human SLC12A5 and SOX18, respectively, were constructed by subcloning the PCR‐amplified human *SLC12A5* and *SOX18* coding sequences into vector pMSCV (Clontech). Construction of the SLC12A5 short hairpin RNA (shRNA) lentiviral expression vector has been described previously.[^13^](#cas14502-bib-0013){ref-type="ref"} shRNA oligonucleotides (ShRNA: AGAGTTGCCAGGGTTACATTT) were cloned into vector pSuper‐retro‐puro resulting in pSuper‐retro‐SOX18‐ShRNA. To obtain the recombinant lentiviruses, these vectors were then packaged into 293T cells. The recombinant lentiviruses were then used to produce stable overexpression or knockdown cell lines from BUC cells, as described previously.[^15^](#cas14502-bib-0015){ref-type="ref"}, [^16^](#cas14502-bib-0016){ref-type="ref"}

For ectopic expression of miR~~‐~~133a‐3p (MIMAT0000427), the primary‐miRNA sequence of miR~~‐~~133a‐3p was synthesized (5′‐CCGGACAATGCTTTGCTAGAGCTGGTAAAATGGAACCAAATCGCCTCTTCAATGGATTTGGTCCCCTTCAACCAGCTGTAGCTATGCATTGATTTTTGAATTC‐3′), and then ligated into the human RNA interference consortium vector pLKO.1 via its *Age*1 and *Eco*R1 sites. To knockdown miR~~‐~~133a‐3p expression, we designed a miR~~‐~~133a‐3p inhibitor (inhibitor‐miR~~‐~~133a‐3p) (Ribobio) together with the appropriate control (inhibitor‐Ctrl). The inhibitor and plasmid constructs were transfected into cells using Lipofectamine 3000 (Invitrogen). In summary, the p3000 fraction and plasmids were mixed at a certain ratio, and then added to the cells. Inhibitors and mimics were incubated directly with the Lipofectamine 3000 fraction and added to the cells according to the manufacturer's protocol.

2.3. qRT‐PCR {#cas14502-sec-0005}
------------

Total RNA from BUC tissues and cell lines was extracted using TRIzol reagent (Invitrogen). SYBR Green SuperMix (Roche Molecular Systems Inc) was used to carry out qRT‐PCR together with an ABI7900HT Fast Real‐Time PCR system (Applied Biosystems). GAPDH (encoding glyceraldehyde‐3‐phosphate dehydrogenase) was used as the internal control. PCR primer sequences were: SLC12A5, forward: 5′‐GCAGGAGCCATGTACATCCT‐3′ and reverse: 5′‐CCATGCAGGTGAGCACACA‐3′; SOX18, forward: 5′‐TTCGACCAGTACCTCAACTGC‐3′ and reverse: 5′‐GACATGGAACCAAACATACACG‐3′; MMP7, forward: 5′‐CAGGAAGCCGGAGAAGTGAC‐3′ and reverse: 5′‐TCTCCGGCAAACCGAAGAAC‐3′; GAPDH, forward: 5′‐GGAGATTGTTGCCATCAACG‐3′ and reverse: 5′‐TTGGTGGTGCAGGATGCATT‐3′. Relative expression levels of MMP7, SOX18, and SLC12A5 are shown as --ΔC~T~ (cycle threshold) values.

2.4. Western blotting and drug administration {#cas14502-sec-0006}
---------------------------------------------

Cells were lysed using lysis buffer to obtain total proteins, which were separated using 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore). PVDF membranes were blocked for 1 h, then the membranes were incubated with monoclonal antibodies overnight at 4°C. Secondary antibodies were then reacted with the membranes for 1 h at room temperature. Enhanced chemiluminescence (ECL kit, Santa Cruz Biotechnology Inc) was used to visualize the immunoreactive protein bands and the band intensities were analyzed using the Quantity One system (Bio‐Rad). Primary antibodies comprised: anti‐SLC12A5 (1:1000 dilution, Abcam), anti‐SOX18 (1:1000 dilution, Cell Signaling Technology), anti‐MMP7 (1:1000 dilution, Abcam), anti‐MMP2 (1:800 dilution, Abcam), anti‐MMP9 (1:1000 dilution, Abcam), and anti‐GAPDH (1:5000 dilution, Cell Signaling Technology). For western blotting experiments, CHX was used at 100 μg/mL for 24 h (Sigma‐Aldrich).

2.5. IHC staining {#cas14502-sec-0007}
-----------------

After staining with primary antibodies, a Dako Real Envision Kit (Dako) was used to visualize protein expression, according to the manufacturer\'s instructions. Two independent experienced pathologists scored the staining intensity manually. To evaluate IHC staining, previously published scoring criteria for SLC12A5,[^13^](#cas14502-bib-0013){ref-type="ref"} SOX18,[^17^](#cas14502-bib-0017){ref-type="ref"} or MMP7[^13^](#cas14502-bib-0013){ref-type="ref"} were used. Primary antibodies comprised: anti‐SLC12A5 (1:100 dilution, Abcam), anti‐SOX18 (1:200 dilution, Cell Signaling Technology), and anti‐MMP7 (1:1000 dilution, Abcam).

2.6. Immunofluorescence {#cas14502-sec-0008}
-----------------------

BUC cells were grown on confocal dishes (Corning Inc), rinsed twice with PBS and then fixed for 15 min using 4% paraformaldehyde in PBS on ice. Cells were washed 3 times with PBS, and then permeabilized using 0.1% Triton X‐100 in PBS on ice for 10 min. After washing twice with PBS, they were blocked using 5% BSA in PBST at 37°C for 30 min. Cells were then incubated with primary antibodies at 37°C for 1 h. Cells were washed with PBST, then cells were incubated with the corresponding secondary antibodies for 30 min at 37°C. The cells were then stained with DAPI to stain the nuclei. Fluorescent images were acquired using an OLYMPUS FV1000 confocal microscope (Olympus). Relative mean fluorescence densities were analyzed using ImageJ software (NIH) and plots were constructed using GraphPad Prism 6 software (GraphPad Software, Inc).

2.7. Co‐IP {#cas14502-sec-0009}
----------

Cell extracts were incubated with protein A‐agarose and antibodies (Pierce Biotechnology) overnight at 4°C. Negative controls comprised normal mouse or rabbit IgG (Santa Cruz Biotechnology). Proteins were washed 5 times using lysis buffer (radioimmunoprecipitation assay (RIPA) buffer; Beyotime, Jiangsu, China; P0013), and then 2× SDS sample buffer was used to elute the proteins bound to the beads by boiling for 8 min at 100°C. Western blotting was then used to analyze the samples.

2.8. GST‐pull‐down {#cas14502-sec-0010}
------------------

Reverse transcription PCR was used to isolate the *SLC12A5* cDNA, which was cloned into GST‐tagged pGEX‐4T‐1 vector via the *Xho*I and *Eco*RI sites using T4 DNA Ligase (Thermo Scientific). *SOX18* cDNA was also cloned into the *Xho*I and *Eco*RI sites of the His‐tagged pET‐28a(+) vector. Recombinant plasmids pET‐28a(+)‐SOX18p and GEX‐4T‐1‐SLC12A5 were transformed separately into *Escherichia coli* BL21(DE3). Screening and identification of positive clones synthesizing high levels of recombinant GST‐SLC12A5 or His‐SOX18 proteins were assessed using double enzyme digestion, PCR identification, and DNA sequencing. Purified GST‐SLC12A5 fusion proteins were then linked to Glutathione Sepharose (GE Healthcare), mixed, and reacted with purified His‐SOX18 at 4°C overnight. Western blotting analysis using anti‐GST antibodies (TransGen Biotechnology) and anti‐His tag antibodies (Beijing, China) was used to detect the proteins in the eluted samples.

2.9. Chromatin immunoprecipitation (ChIP) assay {#cas14502-sec-0011}
-----------------------------------------------

ChIP assay was conducted using an EZ ChIP™ Chromatin Immunoprecipitation Kit (Millipore). In summary, sonication was used to break the crosslinked chromatin into 200‐1000 bp fragments. Anti‐SOX18 (1:200 dilution, Cell Signaling Technology) and anti‐MMP7 (1:1000 dilution, Abcam) antibodies were then used to immunoprecipitate the chromatin.

2.10. 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay {#cas14502-sec-0012}
------------------------------------------------------------------------------

Cell viability was measured using an MTT assay (Sigma‐Aldrich). Briefly, seeded cells were cultured in 96‐well plates. The manufacturer\'s procedures for the MTT assay were then followed to examine cell viability.

2.11. Transwell assays {#cas14502-sec-0013}
----------------------

After resuspension in 200 μl serum‐free medium, 3.0 × 10^4^ BUC cells were added to the upper section of a Transwell chamber (Corning; 24‐well insert, pore size: 8 mm). Fetal bovine serum (15%) was added to the lower section as a chemoattractant. For the migration assay, the Transwell apparatus was incubated for 48 h. Thereafter, adherent cells on the upper surface of the membrane were discarded, and those on the lower surface were fixed, followed by staining with 0.1% crystal violet. For each insert, cells were counted visually in 5 randomly chosen fields under a light microscope.

2.12. Luciferase reporter assay {#cas14502-sec-0014}
-------------------------------

A psiCHECK‐2‐SLC12A5‐3′‐UTR reporter and the miR‐133a‐3p mimics or negative control, were co‐transfected into BUC cells. At 36 h later, a Dual‐Luciferase Reporter Assay System (Promega) was then used to analyze the collected cells.

Next 100 ng of the SOX18 luciferase reporter plasmid or the control‐luciferase plasmid, together with 1 ng of the pRL‐TK Renilla plasmid (Promega), were transfected into cells using Lipofectamine 3000, according to the manufacturer\'s instructions. Then, 24 h later, the Renilla and Luciferase signals were detected using the Dual‐Luciferase Reporter Assay Kit (Promega).

2.13. Care and maintenance of the experimental animals {#cas14502-sec-0015}
------------------------------------------------------

All procedures involving mice were approved by the Institutional Animal Care and Use Committee of the Third Xiangya Hospital of Central South University. Intravenous injection of 5 × 10^5^ BUC cells into the tail vein of 4‐wk‐old BALB/c nude mice was used to establish the in vivo metastasis model. The mice were sacrificed at 6 wk after injection. Lungs were excised before being fixed using phosphate‐buffered formalin. Subsequently, for each block of the lung, consecutive tissue sections were obtained. We carefully enumerated the pulmonary metastatic nodules in the lungs.

2.14. Statistical analysis {#cas14502-sec-0016}
--------------------------

In the BUC cohorts, SPSS software (SPSS Standard version 16.0; IBM Corp.) was used to carry out the statistical analysis. Statistical significance of the association of SLC12A5 expression with the patients' clinicopathological parameters and their correlations were assessed using the χ^2^ test. Primary end points were OS. OS was assessed via Kaplan‐Meier analysis, and comparisons of OS data were performed using the log‐rank test. For multivariate analysis, the Cox regression model was used. Mean ± SD was used to express all the data. To assess differences within treatment groups Dunnett *t* test and two‐factor analysis of variance were used. Statistical significance was accepted at *P* \< .05.

3. RESULTS {#cas14502-sec-0017}
==========

3.1. Expression of SLC12A5 in BUC {#cas14502-sec-0018}
---------------------------------

SLC12A5 expression in patients with BUC was studied by recruiting 2 independent BUC cohorts, in which 112 and 126 BUC tissue samples were collected, respectively. The clinicopathological characteristics of the patients studied are summarized in Table [1](#cas14502-tbl-0001){ref-type="table"}. Using previously reported criteria, 59/112 (52.7%) BUC patients in the learning cohort and in 66/126 (52.4%) BUC patients in the validation cohort showed high SLC12A5 expression (Figure [1A‐D](#cas14502-fig-0001){ref-type="fig"}). In both the learning and validation cohorts, correlation analysis demonstrated that high SLC12A5 expression was associated significantly with higher grade, advanced T and N status, and adjuvant chemotherapy (*P* \< .05; Table [1](#cas14502-tbl-0001){ref-type="table"}).

![Immunohistochemical staining of SLC12A5 in BUC tissues and its prognostic significance in patients with BUC. A, BUC case (case 6) exhibiting low expression of SLC12A5, in which less than 20% of carcinoma cells showed positive staining for SLC12A5. B‐D, High expression of SLC12A5 was observed in other BUC (cases 21, 45, 78), in which more than 80% of carcinoma cells demonstrated positive staining for SLC12A5. E, F High expression of SLC12A5 was associated with poor prognosis of patients with BUC. Kaplan‐Meier plots show the overall survival curves of 112 patients with BUC in the learning cohort (E) and 126 patients with BUC in the validation cohort (F), according to SLC12A5 expression levels in the primary tumor (*P* \< .05, log‐rank test)](CAS-111-2349-g001){#cas14502-fig-0001}

3.2. Expression of SLC12A5 predicts poor OS for patients with BUC {#cas14502-sec-0019}
-----------------------------------------------------------------

In the learning and validation cohorts, univariate analysis showed that poor OS for patients with BUC correlated with high SLC12A5 expression (*P* \< .001 and *P* = .002, respectively; Figure [1E,F](#cas14502-fig-0001){ref-type="fig"}; Table [S1](#cas14502-sup-0009){ref-type="supplementary-material"}). In both cohorts, Kaplan‐Meier analysis also revealed a significant effect of number of clinicopathological prognostic parameters, including pT status (*P* = .009 and *P* \< .001, respectively; Table [S1](#cas14502-sup-0009){ref-type="supplementary-material"}), pN status (*P* \< .001 and *P* \< .001, respectively; Table [S1](#cas14502-sup-0009){ref-type="supplementary-material"}), and adjuvant chemotherapy (*P* \< .001 and *P* \< .001, respectively; Table [S1](#cas14502-sup-0009){ref-type="supplementary-material"}) on OS. In the learning cohort, multivariate analysis demonstrated that pN status and SLC12A5 expression were independent predictors of patient OS (*P* = .001 and *P* \< .001, respectively; Table [2](#cas14502-tbl-0002){ref-type="table"}). This result was verified in the validation cohort (*P* = .019 and *P* = .026, respectively; Table [2](#cas14502-tbl-0002){ref-type="table"}).

###### 

Multivariate Cox regression analysis for overall survival in BUC patients

  Feature                                    Learning cohort   Learning cohort                                
  ------------------------------------------ ----------------- ----------------- ------ ------- ------------- ------
  pT status (pTa/pT1 vs pT2 vs pT3 vs pT4)   0.759             0.667‐1.344       .947   1.626   0.959‐2.756   .071
  pN status (pN− vs pN+)                     2.132             1.023‐4.446       .043   2.653   1.070‐6.580   .035
  Adjuvant chemotherapy (no vs yes)          2.045             0.889‐4.704       .092   1.188   0.376‐3.755   .769
  SLC12A5 expression (low vs high)           3.623             1.707‐7.689       .001   1.997   0.967‐4.124   .041

Abbreviations: BUC, bladder urothelial carcinoma; CI, confidence interval; HR, hazard ratio.
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3.3. In vitro and in vivo BUC cell invasion and migration are promoted by SLC12A5 overexpression {#cas14502-sec-0020}
------------------------------------------------------------------------------------------------

To study the function of SLC12A5 in BUC cells, SLC12A5 expression in one normal bladder uroepithelial cell line (SV‐HUV‐1) and 7 BUC cell lines was examined. qRT‐PCR and western blotting assays showed higher expression of SLC12A5 in 4 BUC cell lines (EJ, T24, BIU87, and RT4) and lower SLC12A5 levels in 3 BUC cell cells (J82, 5637, and UM‐UC‐3) and in the normal SV‐HUV‐1 cells (Figure [2A,B](#cas14502-fig-0002){ref-type="fig"}). Previously, we reported that BUC cell invasion and metastasis was inhibited by downregulation of SLC12A5 in vitro and in vivo.[^13^](#cas14502-bib-0013){ref-type="ref"} Next, we studied the effect of SLC12A5 overexpression on in vitro and in vivo BUC cell invasion and metastasis. SLC12A5 was overexpressed in 5637 and UM‐UC‐3 cell lines (Figure [2C,D](#cas14502-fig-0002){ref-type="fig"}). A proliferation assay revealed that SLC12A5 overexpression had no effect on the growth of UM‐UC‐3 and 5637 cells (Figure [S1A,B](#cas14502-sup-0001){ref-type="supplementary-material"}). However, Boyden chamber assays demonstrated that SLC12A5 increased the migration of 5637 and UM‐UC‐3 cells across the Transwell membrane by 3‐fold to 4‐fold (Figure [2E](#cas14502-fig-0002){ref-type="fig"}). Similarly, the numbers of 5637 and UM‐UC‐3 cells that invaded through Matrigel in the Transwell insert were also significantly increased by SLC12A5 overexpression (Figure [2F](#cas14502-fig-0002){ref-type="fig"}). Next, we studied the effect of SLC12A5 overexpression on BUC metastasis to the lungs after intravenous tail vein delivery of BUC cells. In the lungs of mice, H&E staining revealed that the metastatic burden was significantly increased 6 wk after injection of 5637 and UM‐UC‐3 cells overexpressing SLC12A5 (Figure [2G](#cas14502-fig-0002){ref-type="fig"}). These data indicated that overexpression of SLC12A5 promoted BUC cells invasiveness and metastasis in vitro and in vivo.

![Overexpression of SLC12A5 promotes BUC invasion and metastasis in vitro and in vivo. A, B, qRT‐PCR and western blotting showing the relative expression of SLC12A5 mRNA (A) and protein (B) in several BUC cell lines and normal bladder uroepithelial cell line SV‐HUV‐1. C, D, qRT‐PCR and western blotting showing the relative expression of SLC12A5 mRNA (C) and protein (D) after overexpressing SLC12A5 in 5637 and UM‐UC‐3 cell lines. E, F, Transwell migration assays showing that overexpression of SLC12A5 promoted the migration (E) and invasion (F) of 5637 and UM‐UC‐3 cell lines. G, Tail vein injection lung metastatic models. Number of tumors was compared between the SLC12A5‐vector group and the SLC12A5‐overexpressing group. n = 6. N, normal lung; M, lung metastatic tumor; \*\**P* \< .01](CAS-111-2349-g002){#cas14502-fig-0002}

3.4. SLC12A5 interacts with SOX18 in BUC cells {#cas14502-sec-0021}
----------------------------------------------

Previously, we used gene chip technology to confirm that *MMP7* is the major downstream target gene of SLC12A5 during the induction of BUC invasiveness and metastasis.[^13^](#cas14502-bib-0013){ref-type="ref"} SOX18, one of the 20‐member SOX transcription factor family, shares the characteristic HMG box.[^18^](#cas14502-bib-0018){ref-type="ref"} SOX18 determines cell fate and regulates cell differentiation during embryonic development.[^18^](#cas14502-bib-0018){ref-type="ref"}, [^19^](#cas14502-bib-0019){ref-type="ref"} Previous studies have found that SOX18 is upregulated and enhances cell proliferation and metastasis in various human malignancies, including breast, lung, ovarian, hepatocellular, and bladder cancer.[^17^](#cas14502-bib-0017){ref-type="ref"}, [^20^](#cas14502-bib-0020){ref-type="ref"}, [^21^](#cas14502-bib-0021){ref-type="ref"}, [^22^](#cas14502-bib-0022){ref-type="ref"}, [^23^](#cas14502-bib-0023){ref-type="ref"} The master transcription factor SOX18 has been identified on the promoter of *MMP7*.[^24^](#cas14502-bib-0024){ref-type="ref"} Thus, we determined whether SLC12A5 physically interacts with SOX18. In BUC cells, the expression level of *SOX18* mRNA was unaffected by SLC12A5 overexpression (Figure [3A](#cas14502-fig-0003){ref-type="fig"}); however, in 5637 and UM‐UC‐3 cells, overexpression of SLC12A5 increased the SOX18 protein level; in T24 cells, *SLC12A5* knockdown had the opposite effect (Figure [3B](#cas14502-fig-0003){ref-type="fig"}). Thus, SLC12A5 functions to increase the SOX18 protein level. To further investigate SOX18 control mediated by SLC12A5, the interaction of these 2 proteins was examined. A significant amount of SLC12A5 protein was associated with SOX18 in the Co‐IP assay (Figure [3C](#cas14502-fig-0003){ref-type="fig"}). In 5637 and UM‐UC‐3 cells, confocal microscopy revealed the co‐localization of SOX18 and SLC12A5 (Figure [3D](#cas14502-fig-0003){ref-type="fig"}). To determine whether there is a direct interaction between these 2 proteins, GST‐pull‐down assays were performed using purified His‐tagged SOX18 and GST‐tagged SLC12A5. The results shown in Figure [3E](#cas14502-fig-0003){ref-type="fig"} revealed that purified His‐tagged SOX18 associated with GST‐SLC12A5, but not with GST (Figure [3E](#cas14502-fig-0003){ref-type="fig"}). Moreover, patients with BUC with high SLC12A5 levels frequently showed high expression of SOX18 (Figure [3F](#cas14502-fig-0003){ref-type="fig"}; Table [S2](#cas14502-sup-0010){ref-type="supplementary-material"}). The correlation between SOX18 expression in BUC and several clinicopathologic features was further studied. In the learning cohort, SOX18 expression was positively correlated with smoking history, tumor size, tumor multiplicity, T and N status, and adjuvant chemotherapy (*P* \< .05; Table [S3](#cas14502-sup-0011){ref-type="supplementary-material"}); In the validation cohort, SOX18 expression was positively correlated with gender, tumor size, tumor multiplicity, tumor grade, T and N status, and adjuvant chemotherapy (*P* \< .05, Table [S3](#cas14502-sup-0011){ref-type="supplementary-material"}). Importantly, high expression of SOX18 was associated with poor OS in these 2 cohorts (*P* \< .001 and *P* = .007, respectively; Figure [S2](#cas14502-sup-0002){ref-type="supplementary-material"}). Short hairpin RNA (shRNA) was used to knockdown *SLC12A5* expression to determine whether SLC12A5 modulates SOX18 levels. After 48 and 72 h of shRNA delivery, in SLC12A5‐depleted cells, decreased levels of the SOX18 protein were observed, whereas these was no effect on its mRNA level (Figures [S3](#cas14502-sup-0003){ref-type="supplementary-material"}, [S4](#cas14502-sup-0004){ref-type="supplementary-material"}). Inhibition of protein synthesis by CHX for different times, followed by analysis using western blotting, suggested that SOX18 half‐life was markedly extended after *SLC12A5* knockdown (Figure [S5](#cas14502-sup-0005){ref-type="supplementary-material"}). These data indicated that SLC12A5 directly physically interacts with SOX18 to regulate SOX18 protein stability, and that their expression levels are correlated in BUC.

![SLC12A5 interacts with SOX18. A, BUC cells were transfected with the *SLC12A5* overexpression or knockdown vector. *SOX18* mRNA level was determined. B, Protein level of SOX18 was examined in cells with *SLC12A5* overexpression or knockdown. C, Co‐immunoprecipitation assays of SLC12A5 and SOX18 in T24 and BIU87 cells. T24 and BIU87 cells were transfected with nontargeting shRNA or *SLC12A5* shRNA. Cell lysates were immunoprecipitated with IgG control antibodies or anti‐SOX18 antibodies, and then immunoblotted with anti‐SLC12A5 or anti‐SOX18 antibodies. SLC12A5, SOX18, and GAPDH levels in whole cell lysates (input) are shown. D, BUC cells were fixed in 4% paraformaldehyde and incubated with antibodies overnight at 4°C. Cells were stained with fluorescent secondary antibodies and DAPI, then cells were observed under a confocal fluorescence microscope. E, Purified bacterially expressed His‐SOX18 fusion proteins were mixed with purified bacterially expressed GST or GST‐SLC12A5 fusion proteins. Immunoprecipitated His‐tagged fusion proteins were detected using western blotting analysis with anti‐His antibodies. Lower panels show the inputs of His‐SOX18 and GST‐SLC12A5 fusion proteins in the immunoprecipitation experiment. F, Patients with high expression of the SLC12A5 in BUC tissues frequently showed high expression of SOX18](CAS-111-2349-g003){#cas14502-fig-0003}

3.5. SLC12A5 activates the SOX18 target gene *MMP7* in BUC cells {#cas14502-sec-0022}
----------------------------------------------------------------

To determine whether SLC12A5 regulates SOX18's transcriptional activity, we first performed SOX18 luciferase reporter assays. *SLC12A5* overexpression enhanced the SOX18 luciferase reporter gene activity significantly. By contrast, *SLC12A5* silencing induced a significant decrease in the reporter activity (Figure [4A](#cas14502-fig-0004){ref-type="fig"}). ChIP analysis demonstrated that the *MMP7* promoter region was enriched with SOX18 (Figure [4B](#cas14502-fig-0004){ref-type="fig"}). Moreover, western blotting and qRT‐PCR analyses verified that in 5637 and UM‐UC‐3 cells, SLC12A5 induced transcription of *MMP7* (the SOX18 target gene). However, *MMP7* expression was significantly attenuated by *SLC12A5* knockdown in T24 cells (Figure [4C,D](#cas14502-fig-0004){ref-type="fig"}). Additionally, patients with BUC who had high SLC12A5 levels frequently showed high expression of MMP7 (Table [S2](#cas14502-sup-0010){ref-type="supplementary-material"}). Western blotting showed that SLC12A5 overexpression had no effect on the expression of other MMPs, such as MMP2 and MMP9 in UM‐UC‐3 and 5637 cells (Figure [S6](#cas14502-sup-0006){ref-type="supplementary-material"}). These results indicated that SLC12A5 colocalizes with SOX18 and activates its target gene *MMP7* in BUC cells.

![SLC12A5 regulates the expression of SOX18 target gene *MMP7* in BUC cells. A, SOX18 luciferase reporter activities were analyzed in the indicated cells. Each bar represents the mean ± SD of 3 independent experiments. B, ChIP assay using anti‐SOX18 antibodies to test the enrichment at the *MMP7* promoter. C, *MMP7* mRNA level was examined in BUC cells with *SLC12A5* overexpression or knockdown. D, Protein level of MMP7 was examined in cells with *SLC12A5* overexpression or knockdown; \*\**P* \< .01](CAS-111-2349-g004){#cas14502-fig-0004}

3.6. SOX18 or MMP7 inhibition impairs SLC12A5‐induced BUC cell progression {#cas14502-sec-0023}
--------------------------------------------------------------------------

SLC12A5 can enhance SOX18 transactivation ability; therefore, we sought to determine whether SOX18 transactivation is required for SLC12A5‐induced BUC cell progression. The results of western blotting demonstrated that SOX18 levels increased in BUC cells after the overexpression of *SLC12A5* (Figure [S7A](#cas14502-sup-0007){ref-type="supplementary-material"}). Moreover, in 5637 and UM‐UC‐3 cells that overexpressed SLC12A5, *SOX18* knockdown led to rescued SOX18 levels (Figure [S7A](#cas14502-sup-0007){ref-type="supplementary-material"}). Boyden chamber assays showed that SLC12A5‐related enhanced 5637 and UM‐UC‐3 cell migration and invasion were abolished after treatment with the *SOX18* shRNA (Figure [S7B,C](#cas14502-sup-0007){ref-type="supplementary-material"}). In addition, *MMP7* knockdown rescued the ability of SLC12A5 overexpression to promote 5637 and UM‐UC‐3 cell migration and invasion (Figure [S7D,E](#cas14502-sup-0007){ref-type="supplementary-material"}). Taken together, these findings indicated that SLC12A5 activates *MMP7* expression by interacting with SOX18, which mediates the migration and invasion of BUC.

3.7. SLC12A5 is targeted by miR‐133a‐3p in BUC {#cas14502-sec-0024}
----------------------------------------------

starBase prediction program (<http://starbase.sysu.edu.cn/starbase2/index.ph>) was used to perform bioinformatic analysis to identify miRNAs that might regulate SLC12A5. This was achieved by comparing the predicted miRNAs with those identified as being downregulated in BUC tumor tissues in previously published miRNA profiles (NCBI/GEO/[GSE76211](http://GSE76211); NCBI/GEO/[GSE39093](http://GSE39093)). Screening of the 2 datasets identified only one common miRNA, miR‐133a‐3p. A putative binding site for miR‐133a‐3p in the *SLC12A5* 3′ untranslated region (UTR) was identified (Figure [5A](#cas14502-fig-0005){ref-type="fig"}). In T24 and 5637cells, miR‐133a‐3p overexpression markedly reduced the protein and mRNA levels of SLC12A5 (Figure [5B‐D](#cas14502-fig-0005){ref-type="fig"}). Whereas downregulation of miR‐133a‐3p had the opposite effects (Figure [5B‐D](#cas14502-fig-0005){ref-type="fig"}). The activity of the wild‐type 3′UTR of *SLC12A5* was attenuated by miR‐133a‐3p overexpression, but it had no effect on the activity of the mutant 3′UTR, as shown by dual‐luciferase reporter assay (Figure [5E](#cas14502-fig-0005){ref-type="fig"}). In clinical samples, the *SLC12A5* mRNA level was inversely proportional to the expression level of miR‐133a‐3p (Figure [5F](#cas14502-fig-0005){ref-type="fig"}). These results implied that in BUC cells, miR‐133a‐3p modulates the expression of *SLC12A5*.

![SLC12A5 is targeted by miR‐133a‐3p. A, Putative binding site for miR‐133a‐3p in the *SLC12A5* 3′UTR. B, C, T24 and 5637 cells were transfected with miR‐133a‐3p mimics for 36 h. *SLC12A5* mRNA levels were determined using qRT‐PCR. D, Proteins from T24 and 5637 cells treated with miR‐133a‐3p mimics or miR‐133a‐3p inhibitors were subjected to western blotting to examine the levels of SLC12A5. E, Luciferase reporter assays were performed to indicate the effect of miR‐133a‐3p on the activity of the *SLC12A5* mRNA 3′UTR. F, Correlation between *SLC12A5* mRNA and miR‐133a‐3p was determined in 20 BUC samples. G, H, Impact of SLC12A5 on miR‐133a‐3p‐mediated cell migration was determined by Transwell migration (G) and Matrigel invasion (H) assays; \**P* \< .05, \*\**P* \< .01](CAS-111-2349-g005){#cas14502-fig-0005}

Our results validated previous reports[^25^](#cas14502-bib-0025){ref-type="ref"}, [^26^](#cas14502-bib-0026){ref-type="ref"} that miR‐133a‐3p functions as a tumor suppressor in BUC (Figure [5G](#cas14502-fig-0005){ref-type="fig"},H). We then determined the effect of SLC12A5 on miR‐133a‐3p‐induced phenotypes. SLC12A5 overexpression in miR‐133a‐3p‐BUC cells abrogated miR‐133a‐3p‐induced suppression of BUC cell migration and invasion (Figure [5G](#cas14502-fig-0005){ref-type="fig"},H). Additionally, miR‐133a‐3p decreased SOX18 and MMP7 expression was increased by overexpression of SLC12A5 in T24‐miR‐133a‐3p cells (Figure [S8](#cas14502-sup-0008){ref-type="supplementary-material"}). Taken together, these results implied that SLC12A5 participates in miR‐133a‐3p's tumor suppressive activity.

4. DISCUSSION {#cas14502-sec-0025}
=============

In this study, we demonstrated frequent upregulation of SLC12A5 in BUC that correlated significantly with malignant phenotypes such as poorer survival rates and metastasis. SLC12A5 might be an independent prognostic biomarker of poorer outcome in BUC, as demonstrated by multivariate analyses. In accordance with the results reported in our previous study,[^13^](#cas14502-bib-0013){ref-type="ref"} our data suggested that SLC12A5 overexpression markedly increased BUC cells' migratory ability through their expression of SOX18, which then transcriptionally activates expression of its downstream target *MMP7*. These findings identified SLC12A5, SOX18, and MMP7 as potential prognostic markers that might help to guide individual therapeutic management of patients with BUCs.

Although MMPs are the major downstream target genes through which SLC12A5 has been proposed to promote tumor progression and metastasis,[^12^](#cas14502-bib-0012){ref-type="ref"} the underlying molecular mechanisms remain unclear. In BUC, SLC12A5's oncogenic function promoted tumor progression and metastasis via its expression of SOX18. SOX18 regulates cell differentiation and determines cell fate during embryonic development.[^18^](#cas14502-bib-0018){ref-type="ref"}, [^19^](#cas14502-bib-0019){ref-type="ref"} Saitoh and colleagues first observed the increased expression of SOX18 in various cancer cell lines[^27^](#cas14502-bib-0027){ref-type="ref"} and, subsequently, studies have shown that in several types of cancer, such as bladder, lung, pancreatic, and breast cancers, SOX18 is upregulated and is a marker of poor patient prognosis.[^20^](#cas14502-bib-0020){ref-type="ref"}, [^22^](#cas14502-bib-0022){ref-type="ref"}, [^23^](#cas14502-bib-0023){ref-type="ref"}, [^28^](#cas14502-bib-0028){ref-type="ref"} Acting as a master transcription factor, SOX18 activates prosurvival signaling pathways, which results in cancer cell migration and proliferation. Moreover, SOX18 could promote prostate cancer growth and metastasis by upregulating *MMP7* expression.[^29^](#cas14502-bib-0029){ref-type="ref"} The results of the present study showed that SLC12A5 is physically bound to SOX18, and then transcriptionally activates the expression of the downstream target gene *MMP7*. Moreover, SLC12A5‐promoted cell progression was markedly abolished by inhibition of SOX18 or MMP7. Thus, in BUC, the SLC12A5/SOX18/MMP7 axis could be a therapeutic target.

Dysregulation of microtubule proteins is caused by post--transcriptional modulation of mRNA. As far as we know, there has been no report of *SLC12A5* being targeted by miRNAs. Here, miR‐133a‐3p was identified as an upstream regulator that suppresses *SLC12A5* expression in BUC cells. Cell migration could be markedly inhibited by miR‐133a‐3p overexpression, however this effect was attenuated markedly after SLC12A5 overexpression. The results also indicated that miR‐133a‐3p caused a reduction in SLC12A5 expression by suppressing *SLC12A5* promoter activity. Previous studies have reported the role of miR‐133a‐3p in BUC.[^25^](#cas14502-bib-0025){ref-type="ref"}, [^26^](#cas14502-bib-0026){ref-type="ref"}, [^30^](#cas14502-bib-0030){ref-type="ref"}, [^31^](#cas14502-bib-0031){ref-type="ref"} Their data showed that in BUC, downregulation of miR‐133a‐3p expression suggested that its acts as a tumor suppressor via its interactions with, for example, the EGFR.[^31^](#cas14502-bib-0031){ref-type="ref"}

In summary, SLC12A5 promoted in vitro BUC cell migration and invasion and metastasis of BUC xenografts in nude mice. SOX18 expression is required for these effects, and the subsequent enhanced expression of *MMP7*, which contribute to BUC progression. Our data demonstrated that SLC12A5 functions as an oncogene via SOX18‐mediated *MMP7* expression. In BUC tissues, downregulation of miR‐133a‐3p results in SLC12A5 upregulation, and poor patient prognosis is associated with SLC12A5 overexpression. The newly identified miR‐133a‐3p/SLC12A5/SOX18/MMP7 axis might be developed as a therapeutic target to treat BUC.
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